Enhancing Oncology Notable Health Workflows with Prior Auth Automation

Klivira's integration capabilities are designed to enhance **oncology Notable Health** workflows, transforming the complex prior authorization landscape for cancer care providers. Our platform automates the submission and tracking of PAs, ensuring timely access to critical treatments.

Oncology prior authorization is notoriously complex, characterized by high-cost regimens, frequent changes, and urgent treatment timelines. For health systems leveraging automation platforms like Notable Health for patient intake and RCM, integrating a specialized PA solution is crucial to address these unique challenges. Klivira extends these capabilities by providing deep prior authorization automation tailored for the oncology specialty.

Addressing the Unique Prior Authorization Burden in Oncology

Oncology prior authorization presents a distinct operational challenge due to its high volume, high-cost therapies, and the critical urgency of treatment initiation. Unlike many other specialties, cancer care often requires dozens of PA events per patient across diagnosis, staging, multiple treatment lines, and supportive care, placing immense strain on revenue cycle teams and delaying patient access to life-saving therapies.

Common Prior Authorization Triggers in Oncology

J-code chemotherapy and biologic infusions, including immunotherapies and targeted therapies.
Advanced imaging for staging and surveillance (PET/CT, advanced MRI, tumor-specific molecular imaging).
Radiation oncology procedures (IMRT, IGRT, SBRT, brachytherapy, proton-beam therapy CPT ranges).
Genetic and molecular testing for treatment selection and risk stratification.
Specialty oral oncolytics and supportive care medications (G-CSF, ESAs, bone-targeting agents).

Optimizing Oncology Notable Health Workflows with Klivira

For organizations utilizing Notable Health to streamline patient intake and revenue cycle management, integrating Klivira provides specialized prior authorization automation that aligns with oncology's unique demands. Klivira complements Notable Health by automating the complex, NCCN-driven PA processes, ensuring that critical treatment approvals for chemotherapy, biologics, and radiation therapy are managed efficiently and accurately, reducing manual burden and accelerating time-to-treatment.

Essential Documentation for Oncology Prior Authorizations

Diagnosis confirmation, including pathology report, tumor staging (AJCC TNM), and relevant molecular markers.
Documentation of prior-line treatment response and rationale for the proposed next regimen.
Patient performance status (ECOG or Karnofsky score) and relevant comorbidities/contraindications.
For off-label use, specific NCCN Compendium citation (Category 1, 2A, 2B) and clinical context.
Radiation oncology treatment plans, including prescribed dose, target volumes, and organ-at-risk constraints.

Streamlining Medical and Pharmacy Benefit PAs in Cancer Care

Oncology medications frequently split across medical benefit (IV infusions via X12 278 or payer portals) and pharmacy benefit (oral oncolytics via PBMs and ePA partners like CoverMyMeds or Surescripts). Klivira's platform intelligently routes PA requests based on the specific drug and benefit, ensuring seamless submission through the correct channels and reducing re-work for your team.

Mitigating Common Prior Authorization Denials in Oncology

Common oncology PA denials stem from issues like off-label use without compendium support, step therapy requirements, and documentation gaps. Klivira's NCCN-compendium-aware policy logic proactively identifies potential denial triggers, guiding staff to provide complete documentation and supporting appeals for clinical-necessity denials, including facilitating peer-to-peer reviews.

Frequently asked questions

How does Klivira specifically address the urgency of oncology prior authorizations?

Klivira's platform prioritizes urgent oncology PAs, leveraging real-time payer connectivity and NCCN-aware logic to accelerate submissions. We streamline the collection of required documentation, minimize manual touchpoints, and provide concurrent PA tracking for multiple events per patient, directly supporting faster time-to-treatment.

What role do NCCN Clinical Practice Guidelines play in Klivira's oncology PA automation?

The NCCN Clinical Practice Guidelines are central to Klivira's oncology PA logic. Our system incorporates NCCN-compendium-aware policy rules, automatically surfacing required documentation based on specific regimens, tumor types, and lines of therapy, ensuring submissions align with established medical necessity criteria.

Can Klivira handle both medical and pharmacy benefit prior authorizations for oncology drugs?

Yes, Klivira is designed to manage the unique split in oncology drug benefits. We route medical benefit PAs (for IV infusions) through appropriate channels like X12 278 or payer portals, and pharmacy benefit PAs (for oral oncolytics) through PBMs and ePA partners, ensuring comprehensive coverage across all drug types.

How does Klivira support frequent regimen changes during oncology treatment?

Klivira's regimen-level PA workflow is built to accommodate the dynamic nature of oncology treatment. Our platform tracks multiple concurrent PA events per patient, allowing for efficient submission of new PAs triggered by regimen modifications due to progression, toxicity, or response, minimizing delays during critical treatment adjustments.

Does Klivira integrate with existing EMRs for oncology workflows?

Yes, Klivira integrates seamlessly with major EMR systems using standards like SMART on FHIR. This integration allows for automated data extraction from clinical notes and order sets, pre-populating PA forms and reducing manual data entry for oncology teams, directly enhancing existing EMR workflows.